GleamWall
中文EN

LIFD LFTD PARTNERS INC.

Pharmaceutical Preparations · OTC · SEC CIK 1391135 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-15.9%
TTM net income YoY-53,461.9%
TTM EPS YoY—
Revenue 3-yr CAGR-14.3%
Net income 3-yr CAGR—

Margins

Gross margin8.3%
Operating margin-27.9%
Net margin-108.9%
FCF margin2.1%
EBITDA margin-26.8%

Returns

ROE-164.2%
ROA-127.1%
ROIC (approx.)-38.3%
Asset turnover1.17x

Leverage & solvency

Liabilities / assets55.7%
Debt / equity0.00x
Current ratio1.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-130.2%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$36.92M$37.33M
Cost of revenue$24.30M$24.57M
Gross profit$12.62M$12.75M
Operating income$913,208-$773,464
Pretax income-$24.43M-$2.38M
Income tax$432,824-$524,425
Net income-$24.86M-$1.86M
EBITDA$1.47M-$252,833
EPS (basic)-1.68-0.13
EPS (diluted)-1.68-0.13
Weighted avg. shares (diluted)14.82M14.80M
Banking
Deposits$1.00M$1.00M
Balance sheet
Cash & equivalents$1.77M$3.15M
Receivables$2.53M$2.66M
Inventory$10.96M$9.32M
Current assets$15.69M$17.23M
PP&E, net$2.27M$2.70M
Goodwill$0$23.09M
Intangibles$0—
Total assets$19.27M$47.62M
Current liabilities$5.16M$6.39M
Total liabilities$6.64M$10.12M
Shareholders' equity$12.63M$37.50M
Shares outstanding14.82M14.82M
Cash flow statement
Operating cash flow$1.32M-$960,067
Capital expenditure$121,639$313,763
Free cash flow$1.20M-$1.27M
Investing cash flow-$121,639-$479,574
Financing cash flow-$2.58M-$770,951
Depreciation & amortization$552,877$520,631
Share buybacks$0$240,240

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.